Role of immune activation in progression to AIDS

Current Opinion in HIV and AIDS

Volumn 11, Issue 2, 2016, Pages 131-137

  Utay, Netanya S ^a   Hunt, Peter W ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; HIV infection; immune activation; monocyte activation; non AIDS events

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; FIBROSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE ACTIVATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; LEUKOCYTE ACTIVATION; LYMPHATIC SYSTEM DISEASE; LYMPHOID TISSUE FIBROSIS; MONOCYTE ACTIVATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNITY; IMMUNOLOGY; MONOCYTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; DISEASE PROGRESSION; HIV-1; HUMANS; IMMUNE SYSTEM PHENOMENA; INTERFERON TYPE I; MONOCYTES;

EID: 84957646468     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0000000000000242     Document Type: Review

References (77)

1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981; 305: 1425-1431.
2. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179: 859-870.
3. Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6: 904-912.
4. Fahey JL, Taylor JM, Manna B, et al. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4+ T-cell measurements. AIDS 1998; 12: 1581-1590.
5. Hunt PW, Martin JN, Sinclair E, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187: 1534-1543.
6. Solomon A, Cameron PU, Bailey M, et al. Immunological and virological failure after antiretroviral therapy is associated with enhanced peripheral and thymic pathogenicity. J Infect Dis 2003; 187: 1915-1923.
7. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201: 1788-1795.
8. Almeida CA, Price P, French MA. Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18: 1351-1355.
9. Kaufmann GR, Zaunders JJ, Cunningham P, Cooper DA. Phenotypic analysis of CD8+ T lymphocytes in a cohort of HIV type 1-infected patients treated with saquinavir, ritonavir, and two nucleoside analogs for 1 year, and association with plasma HIV type 1 RNA. AIDS Res Hum Retroviruses 1999; 15: 963-972.
10. Wada NI, Jacobson LP, Margolick JB, et al. The effect of HAART-induced HIV suppression on circulating markers of inflammation and immune activation. AIDS 2015; 29: 463-471.
11. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59: 1787-1797.
12. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral Therapy Initiated Within 6 Months of HIV Infection Is Associated With Lower T-Cell Activation and Smaller HIV Reservoir Size. J Infect Dis 2013; 208: 1202-1211.
13. Burdo TH, Lentz MR, Autissier P, et al. Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy. J Infect Dis 2011; 204: 154-163.
14. Utay N, Ananworanich J, Slike B, et al. Inflammation Persists Despite Early Initiation of ART in Acute HIV Infection. In: in the Program and Abstracts from the 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Abstract #47.
15. Lee SA, Sinclair E, Jain V, et al. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis 2014; 210: 374-382.
16. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373: 795-807.
17. Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373: 808-822.
18. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9: 139-147.
19. Hunt PW, Sinclair E, Rodriguez B, et al. Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. J Infect Dis 2014; 210: 1228-1238.
20. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-Cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210: 1248-1259.
21. Byakwaga H, Hunt PW, Laker-Oketta M, et al. The kynurenine pathway of tryptophan catabolism and AIDS-associated Kaposi's sarcoma in Africa. J Acquir Immune Defic Syndr 2015; 70: 296-303.
22. Hunt PW, Cao HL, Muzoora C, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS 2011; 25: 2123-2131.
23. Lee SA, Byakwaga H, Boum Y, et al. Immunologic Pathways That Predict Mortality in HIV+Ugandans Initiating ART. In: in the Program and Abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Abstract #317.
24. Baker JV, Hullsiek KH, Singh A, et al. Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. AIDS 2014; 28: 831-840.
25. Sinclair E, Ronquillo R, Lollo N, et al. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr 2008; 47: 544-552.
26. Burdo TH, Weiffenbach A, Woods SP, et al. Elevated sCD163 is a marker of neurocognitive impairment in HIV infection. AIDS 2013; 27: 1387-1395.
27. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20: 2275-2283.
28. Sacre K, Hunt PW, Hsue PY, et al. A role for cytomegalovirus-specific CD4+ CX3CR1+ T cells and cytomegalovirus-induced T-cell immunopathology in HIV-associated atherosclerosis. AIDS 2012; 26: 805-814.
29. Lichtner M, Cicconi P, Vita S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. J Infect Dis 2015; 211: 178-186.
30. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004; 104: 942-947.
31. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002; 29: 346-355.
32. Savarino A, Bottarel F, Malavasi F, Dianzani U. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS 2000; 14: 1079-1089.
33. Catalfamo M, Wilhelm C, Tcheung L, et al. CD4+ and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, Type I IFN, and IL-7. J Immunol 2011; 186: 2106-2116.
34. Lee SA, Sinclair E, Hatano H, et al. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One 2014; 9: e89444.
35. Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2, 3-dioxygenase. J Exp Med 2002; 196: 459-468.
36. Boasso A, Herbeuval JP, Hardy AW, et al. HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2, 3-dioxygenase in plasmacytoid dendritic cells. Blood 2007; 109: 3351-3359.
37. Favre D, Mold J, Hunt PW, et al. Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med 2010; 2: 32ra36.
38. Martinez P, Tsai AC, Muzoora C, et al. Reversal of the Kynurenine Pathway of Tryptophan Catabolism May Improve Depression in ART-Treated HIVInfected Ugandans. J Acquir Immune Defic Syndr 2014; 65: 456-462.
39. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. Neurotox Res 2005; 7: 103-123.
40. Angelovich TA, Hearps AC, Maisa A, et al. Viremic and virologically suppressed HIV infection increases age-related changes to monocyte activation equivalent to 12 and 4 years of aging, respectively. J Acquir Immune Defic Syndr 2015; 69: 11-17.
41. Seu L, Ortiz GM, Burt TD, et al. Levels of circulating myeloid subpopulations and of heme oxygenase-1 do not predict CD4+ T cell recovery after the initiation of antiretroviral therapy for HIV disease. AIDS Res Ther 2014; 11: 27.
42. Liang H, Duan Z, Li D, et al. Higher levels of circulating monocyte-platelet aggregates are correlated with viremia and increased sCD163 levels in HIV-1 infection. Cell Mol Immunol 2015; 12: 435-443.
43. Patro SC, Pal S, Bi Y, et al. Shift in monocyte apoptosis with increasing viral load and change in apoptosis-related ISG/Bcl2 family gene expression in chronically HIV-1-infected subjects. J Virol 2015; 89: 799-810.
44. Bharaj P, Chahar HS, Alozie OK, et al. Characterization of programmed death- 1 homologue-1 (PD-1H) expression and function in normal and HIV infected individuals. PLoS One 2014; 9: e109103.
45. Devevre EF, Renovato-Martins M, Clement K, et al. Profiling of the three circulating monocyte subpopulations in human obesity. J Immunol 2015; 194: 3917-3923.
46. + monocytes is a biomarker of HIV-associated neurocognitive disorders. Neurol Neuroimmunol Neuroinflamm 2014; 1: e36.
47. Chelombitko MA, Shishkina VS, Ilyinskaya OP, et al. A cytofluorometric study of membrane rafts in human monocyte subsets in atherosclerosis. Acta Naturae 2014; 6: 80-88.
48. French MA, Cozzi-Lepri A, Arduino RC, et al. Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. AIDS 2015; 29: 847-851.
49. Verollet C, Souriant S, Bonnaud E, et al. HIV-1 reprograms the migration of macrophages. Blood 2015; 125: 1611-1622.
50. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012; 10: 655-666.
51. Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS 2015; 29: 1263-1265.
52. Funderburg NT, Andrade A, Chan ES, et al. Dynamics of immune reconstitution and activation markers in HIV+treatment-naive patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One 2013; 8: e83514.
53. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal 2013; 18: 2352-2363.
54. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10: 720-727.
55. Eisenhut M. Neopterin in Diagnosis and Monitoring of Infectious Diseases. J Biomarkers 2013; 2013: 196432.
56. van den Borne P, Quax PH, Hoefer IE, Pasterkamp G. The multifaceted functions of CXCL10 in cardiovascular disease. Bio Med Res Int 2014; 2014: 893106.
57. Castley A, Berry C, French M, et al. Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring? PLoS One 2014; 9: e115226.
58. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204: 1227-1236.
59. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308: 379-386.
60. Hattab S, Guiguet M, Carcelain G, et al. Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective firstline combination antiretroviral therapy. HIV Med 2015; 16: 553-562.
61. Knudsen A, Moller HJ, Katzenstein TL, et al. Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis 2013; 13: 230.
62. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
63. Knudsen TB, Petersen J, Møller HJ, et al. Plasma Levels of sCD163 Predict All-Cause Mortality From HIV Infection. In: in the Program and Abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Abstract #316.
64. Krishnan S, Bosch R, Rodriguez B, et al. Smoking and Obesity May Partially Explain the Inflammation and Morbidity Association. In: in the Program and Abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, WA, Abstract #763.
65. Masson L, Passmore JA, Liebenberg LJ, et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis 2015; 61: 260-269.
66. Sandler NG, Bosinger SE, Estes JD, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 2014; 511: 601-605.
67. Rollenhagen C, Macura SL, Lathrop MJ, et al. Enhancing interferon regulatory factor 7 mediated antiviral responses and decreasing nuclear factor kappa B expression limit HIV-1 replication in cervical tissues. PLoS One 2015; 10: e0131919.
68. Zhang Y, Makvandi-Nejad S, Qin L, et al. Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. AIDS 2015; 29: 889-894.
69. Pino M, Erkizia I, Benet S, et al. HIV-1 immune activation induces Siglec-1 expression and enhances viral trans-infection in blood and tissue myeloid cells. Retrovirology 2015; 12: 37.
70. Nguyen TP, Bazdar DA, Mudd JC, et al. Interferon-alpha inhibits CD4+ T cell responses to interleukin-7 and interleukin-2 and selectively interferes with Akt signaling. J Leukoc Biol 2015; 97: 1139-1146.
71. Montaner LJ. Type I IFN in HIV Cure beyond ART. ANRS Satellite Symposium, 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention 2015.
72. Estes JD. Pathobiology of HIV/SIV-associated changes in secondary lymphoid tissues. Immunological reviews 2013; 254: 65-77.
73. Estes JD, Wietgrefe S, Schacker T, et al. Simian immunodeficiency virusinduced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007; 195: 551-561.
74. Keele BF, Jones JH, Terio KA, et al. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 2009; 460: 515-519.
75. Greenwood EJ, Schmidt F, Kondova I, et al. Simian immunodeficiency virus infection of chimpanzees (Pan troglodytes) shares features of both pathogenic and nonpathogenic lentiviral infections. PLoS Pathog 2015; 11: e1005146.
76. Asmuth DM, Pinchuk IV, Wu J, et al. Role of intestinal myofibroblasts in HIVassociated intestinal collagen deposition and immune reconstitution following combination antiretroviral therapy. AIDS 2015; 29: 877-888.
77. Schacker TW, Reilly C, Beilman GJ, et al. Amount of lymphatic tissue fibrosis in HIV infection predicts magnitude of HAART-associated change in peripheral CD4+ cell count. AIDS 2005; 19: 2169-2171.